title: Risk factor burden and control at the time of admission in patients with acute myocardial infarction: Results from the NCDR.
abstract: BACKGROUND
  Understanding risk factor burden and control as well as perceived risk prior to acute myocardial infarction (MI) presentation may identify gaps in contemporary systems of care.
  
  
  METHODS
  Patients presenting with MI in the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines between January 2007 and November 2013 (N = 443,117) were stratified into 5 mutually exclusive risk categories: Framingham Risk Score (FRS) <10% 74,990 (16.9%), FRS 10% to 20% 90,429 (20.4%), FRS >20% 25,701 (5.8%), diabetes without cardiovascular disease (CVD) 67,779 (15.3%), and prior CVD 184,218 (41.6%). Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol (non-HDL-C) goals and statin eligibility were determined based on the Third Adult Treatment Panel.
  
  
  RESULTS
  At presentation, 66.3% met the low-density lipoprotein cholesterol goal, 66.8% met the non-HDL-C goal, 63.7% were nonsmokers, and 65.1% of patients with prior CVD were on aspirin. Only 36.1% of patients met all assessed risk factor control metrics. Overall statin eligibility prior to MI was 60.8%, and 61.1% of statin-eligible patients reported statin use.
  
  
  CONCLUSIONS
  Risk factor control prior to MI was suboptimal, with the majority of individuals failing to meet at least 1 risk factor control metric. More effective system-based interventions are needed to promote adherence to prevention targets.
authors.affiliation: Emory University, Atlanta, GA. Electronic address: andrepaixaobh@gmail.com.
authors.forename: Andre R M
authors.initials: AR
authors.lastname: Paixao
authors.affiliation: University of Missouri-Kansas City, Kansas City, MO.
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Enriquez
authors.affiliation: Duke Clinical Research Institute, Durham, NC.
authors.forename: Tracy Y
authors.initials: TY
authors.lastname: Wang
authors.affiliation: Duke Clinical Research Institute, Durham, NC.
authors.forename: Shuang
authors.initials: S
authors.lastname: Li
authors.affiliation: University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Jarett D
authors.initials: JD
authors.lastname: Berry
authors.affiliation: University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Amit
authors.initials: A
authors.lastname: Khera
authors.affiliation: University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: Sandeep R
authors.initials: SR
authors.lastname: Das
authors.affiliation: University of Texas Southwestern Medical Center, Dallas, TX.
authors.forename: James A
authors.initials: JA
authors.lastname: de Lemos
authors.affiliation: Virginia Commonwealth University, Richmond, VA.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Kontos
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000453:epidemiology*; D050171:Dyslipidemias / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006760:Hospitalization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D012907:Smoking / Q000453:epidemiology*; D014481:United States / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin